JP2018531280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531280A5 JP2018531280A5 JP2018529503A JP2018529503A JP2018531280A5 JP 2018531280 A5 JP2018531280 A5 JP 2018531280A5 JP 2018529503 A JP2018529503 A JP 2018529503A JP 2018529503 A JP2018529503 A JP 2018529503A JP 2018531280 A5 JP2018531280 A5 JP 2018531280A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- appendix
- salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 49
- KMXXSJLYVJEBHI-UHFFFAOYSA-N 3-guanidinopropanoic acid Chemical compound NC(=[NH2+])NCCC([O-])=O KMXXSJLYVJEBHI-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 238000002411 thermogravimetry Methods 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 238000002050 diffraction method Methods 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 150000003890 succinate salts Chemical class 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- 238000001069 Raman spectroscopy Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021077099A JP7134294B2 (ja) | 2015-08-25 | 2021-04-30 | 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209624P | 2015-08-25 | 2015-08-25 | |
| US62/209,624 | 2015-08-25 | ||
| PCT/US2016/048643 WO2017035331A1 (en) | 2015-08-25 | 2016-08-25 | PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021077099A Division JP7134294B2 (ja) | 2015-08-25 | 2021-04-30 | 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531280A JP2018531280A (ja) | 2018-10-25 |
| JP2018531280A6 JP2018531280A6 (ja) | 2018-12-13 |
| JP2018531280A5 true JP2018531280A5 (cg-RX-API-DMAC7.html) | 2019-10-03 |
| JP6880023B2 JP6880023B2 (ja) | 2021-06-02 |
Family
ID=58100994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529503A Active JP6880023B2 (ja) | 2015-08-25 | 2016-08-25 | 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用 |
| JP2021077099A Active JP7134294B2 (ja) | 2015-08-25 | 2021-04-30 | 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021077099A Active JP7134294B2 (ja) | 2015-08-25 | 2021-04-30 | 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20170056352A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3340973B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6880023B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102707964B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114057611A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016311368B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2996520C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3340973T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2843561T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20210044T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE053963T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3340973T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3340973T (cg-RX-API-DMAC7.html) |
| RS (1) | RS61804B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3340973T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017035331A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015168465A1 (en) | 2014-04-30 | 2015-11-05 | Rgenix, Inc. | Inhibitors of creatine transport and uses thereof |
| US20190125745A1 (en) * | 2014-12-17 | 2019-05-02 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018160178A1 (en) * | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| JP2023505687A (ja) | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| KR102615692B1 (ko) * | 2021-10-13 | 2023-12-19 | 주식회사 휴엔켐 | 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물 |
| CN119421865A (zh) * | 2022-04-21 | 2025-02-11 | 默沙东有限责任公司 | 制备附聚的结晶中链脂肪酸钠盐的方法 |
| KR102822799B1 (ko) | 2022-11-09 | 2025-06-20 | 충남대학교산학협력단 | 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA101653A (en) | 1906-08-30 | 1906-10-23 | Herman Besser | Mould |
| US3933797A (en) * | 1972-02-22 | 1976-01-20 | Pfizer Inc. | 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS |
| BE794886A (fr) | 1972-02-22 | 1973-08-02 | Pfizer | Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques |
| US3972872A (en) | 1974-09-23 | 1976-08-03 | Pfizer Inc. | 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids |
| EP0260118B1 (en) | 1986-09-10 | 1991-12-04 | Syntex (U.S.A.) Inc. | Selective amidination of diamines |
| US5676978A (en) * | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
| CA2028593C (en) * | 1989-10-31 | 2007-08-21 | Douglas R. Brandt | Stabilized enzyme compositions |
| DE4334639A1 (de) | 1993-10-11 | 1995-04-13 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten |
| US5994577A (en) | 1994-11-23 | 1999-11-30 | Larsen; Scott D. | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
| DE793646T1 (de) * | 1994-11-23 | 1999-12-30 | Pharmacia & Upjohn Co., Kalamazoo | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
| JP3745439B2 (ja) | 1995-07-06 | 2006-02-15 | 花王株式会社 | 皮膚外用剤 |
| TW453881B (en) | 1995-10-16 | 2001-09-11 | Kao Corp | Cosmetic composition comprising amide derivatives |
| JPH09202710A (ja) * | 1995-11-20 | 1997-08-05 | Kao Corp | しわ改善剤 |
| JP2000511177A (ja) | 1996-05-21 | 2000-08-29 | ファルマシア・アンド・アップジョン・カンパニー | インスリン非依存性糖尿病治療のためのアミノグアニジンカルボキシレート ラクタム類 |
| JP4317599B2 (ja) | 1996-06-26 | 2009-08-19 | 武田薬品工業株式会社 | 徐放性製剤 |
| CN1305376A (zh) | 1998-06-30 | 2001-07-25 | 武田药品工业株式会社 | 治疗糖尿病的药物组合物 |
| EP1656945A1 (en) | 1999-06-05 | 2006-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmaceutical composition comprising oligoarginine |
| ATE356629T1 (de) | 1999-06-05 | 2007-04-15 | Univ Leland Stanford Junior | Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation |
| US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
| US20020082448A1 (en) | 1999-11-08 | 2002-06-27 | The Upjohn Company | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
| US7335723B2 (en) | 2001-08-08 | 2008-02-26 | Merck & Co., Inc. | Melanin-concentrating hormone antagonists |
| JP2005518346A (ja) | 2001-11-07 | 2005-06-23 | メディカル リサーチ カウンセル | ドパミン作動性ニューロンの調節 |
| EP1495046A2 (en) | 2002-01-09 | 2005-01-12 | Merck & Co., Inc. | Selective melanin concentrating hormone type 1 receptor agonists |
| JP2005528424A (ja) | 2002-06-04 | 2005-09-22 | アビセナ グループ インコーポレイティッド | 脳内エネルギー代謝を調節することによって認知機能障害を治療する方法 |
| US20120245211A1 (en) | 2002-06-04 | 2012-09-27 | Children's Hospital Medical Center | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism |
| GB0302882D0 (en) | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| JP4865251B2 (ja) | 2005-05-09 | 2012-02-01 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
| WO2007014756A1 (de) | 2005-08-02 | 2007-02-08 | Alzchem Trostberg Gmbh | Flüssig-formulierung auf basis einer guanidinoessigsäure- komponente |
| US8748567B2 (en) | 2006-05-22 | 2014-06-10 | Children's Medical Center Corporation | Method for delivery across the blood brain barrier |
| WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| AU2007333105A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| DE102007004781A1 (de) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
| BRPI0807157A2 (pt) | 2007-02-08 | 2014-04-29 | Kempharm Inc | Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos |
| CN101848918A (zh) | 2007-09-07 | 2010-09-29 | 吉奇亚公司 | 线粒体组合物及其用途 |
| DE112009000268T5 (de) | 2008-02-06 | 2011-06-01 | Helm Ag | Prasugrel-Salze mit verbesserten Eigenschaften |
| FR2940077B1 (fr) | 2008-12-19 | 2012-07-20 | Oreal | Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante. |
| BRPI0907287B1 (pt) | 2008-12-19 | 2018-01-02 | L'oréal | "processo de clareamento ou de coloração das fibras queratínicas e dispositivo com vários comportamentos" |
| FR2940104B1 (fr) | 2008-12-19 | 2011-08-19 | Oreal | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin |
| JP5866137B2 (ja) | 2009-04-30 | 2016-02-17 | ロレアル | アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置 |
| WO2011031308A1 (en) | 2009-09-09 | 2011-03-17 | Cytokinetics, Incorporated | Novel combinations |
| EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| FR2954160B1 (fr) | 2009-12-22 | 2012-03-30 | Oreal | Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere |
| JP5544024B2 (ja) | 2009-12-31 | 2014-07-09 | ケムファーム・インコーポレーテッド | クエチアピンのアミノ酸結合体、その製造法及び使用法 |
| DE102010012199A1 (de) | 2010-03-19 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Molekular geprägte Polymere für die Eliminierung von Metaboliten |
| FR2958161B1 (fr) | 2010-04-02 | 2012-04-27 | Oreal | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin |
| EP3540059A1 (en) | 2010-04-16 | 2019-09-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| WO2011133348A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| WO2011133150A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| BR112012026768A2 (pt) | 2010-04-21 | 2015-09-29 | Signature Therapeutics Inc | composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores. |
| US20110262359A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| CA2794864A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| US20130281410A1 (en) | 2010-05-13 | 2013-10-24 | University Of Utah Research Foundation | Methods for the treatment of psychiatric disorders |
| EP2399885A1 (en) | 2010-06-22 | 2011-12-28 | Ulrich Dietz | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification |
| WO2012024611A1 (en) | 2010-08-20 | 2012-02-23 | Natural Alternatives International, Inc. | Methods of treating sarcopenia and frailty |
| WO2012047630A2 (en) | 2010-09-27 | 2012-04-12 | Martin Teintze | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use |
| US8765115B2 (en) | 2010-12-01 | 2014-07-01 | National Institute of Agrobiological Scienses | Method of treatment of gastrointestinal disorders with IL-10 |
| CA2827662C (en) | 2011-03-09 | 2020-07-14 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| WO2012122412A2 (en) | 2011-03-09 | 2012-09-13 | Signature Therapeutics, Inc. | Compositions for reducing risk of adverse events caused by drug-drug interactions |
| WO2012138214A1 (en) * | 2011-04-08 | 2012-10-11 | Brewster Lizzy Maritza | Beta-guanidinopropionic acid for the treatment of hypertension |
| WO2012173846A2 (en) | 2011-06-06 | 2012-12-20 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN102850242A (zh) * | 2011-06-27 | 2013-01-02 | 天津天成制药有限公司 | 胍基丙酸硝酸盐的制备方法 |
| US8427223B2 (en) | 2011-07-19 | 2013-04-23 | Lsi Corporation | Voltage level translator circuit for reducing jitter |
| PL2736510T3 (pl) | 2011-07-28 | 2017-07-31 | Kempharm, Inc. | Proleki metylofenidatu, procesy ich wytwarzania i stosowania |
| RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
| FR2983407B1 (fr) | 2011-12-06 | 2014-01-03 | Oreal | Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| PL2854764T3 (pl) | 2012-06-05 | 2019-07-31 | Neuroderm Ltd | Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania |
| CA2877030A1 (en) | 2012-06-22 | 2013-12-27 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
| AU2013337768B2 (en) * | 2012-10-31 | 2015-07-02 | The Rockefeller University | Treatment and diagnosis of colon cancer |
| FR2997846B1 (fr) | 2012-11-09 | 2023-10-20 | Oreal | Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition |
| WO2014138492A1 (en) | 2013-03-08 | 2014-09-12 | Solan, LLC | Methods for fabricating graphite-based structures and devices made therefrom |
| CN103288685B (zh) * | 2013-07-03 | 2015-02-18 | 郭礼强 | 一种3-胍基丙酸的制备方法 |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
-
2016
- 2016-08-24 US US15/245,750 patent/US20170056352A1/en not_active Abandoned
- 2016-08-25 AU AU2016311368A patent/AU2016311368B2/en active Active
- 2016-08-25 CN CN202111189796.6A patent/CN114057611A/zh active Pending
- 2016-08-25 PT PT168401040T patent/PT3340973T/pt unknown
- 2016-08-25 HU HUE16840104A patent/HUE053963T2/hu unknown
- 2016-08-25 RS RS20210023A patent/RS61804B1/sr unknown
- 2016-08-25 CN CN201680057402.2A patent/CN108472269B/zh active Active
- 2016-08-25 PL PL16840104T patent/PL3340973T3/pl unknown
- 2016-08-25 EP EP16840104.0A patent/EP3340973B1/en active Active
- 2016-08-25 SI SI201631048T patent/SI3340973T1/sl unknown
- 2016-08-25 KR KR1020187008144A patent/KR102707964B1/ko active Active
- 2016-08-25 CA CA2996520A patent/CA2996520C/en active Active
- 2016-08-25 HR HRP20210044TT patent/HRP20210044T1/hr unknown
- 2016-08-25 DK DK16840104.0T patent/DK3340973T3/da active
- 2016-08-25 WO PCT/US2016/048643 patent/WO2017035331A1/en not_active Ceased
- 2016-08-25 JP JP2018529503A patent/JP6880023B2/ja active Active
- 2016-08-25 ES ES16840104T patent/ES2843561T3/es active Active
- 2016-09-30 US US15/281,329 patent/US9827217B2/en active Active
-
2017
- 2017-10-27 US US15/795,540 patent/US10512623B2/en active Active
-
2019
- 2019-11-06 US US16/675,669 patent/US20200138759A1/en not_active Abandoned
-
2021
- 2021-04-30 JP JP2021077099A patent/JP7134294B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531280A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512942A5 (cg-RX-API-DMAC7.html) | ||
| ES2460919T3 (es) | Formas polimórficas de p-hidroxibenzoato de (2S)-(4E)-N-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amonio para el tratamiento de trastornos del sistema nervioso central | |
| JP2021530565A5 (cg-RX-API-DMAC7.html) | ||
| KR20120059540A (ko) | Ｃ－ｍｅｔ 조절제를 사용하는 방법 | |
| JP2020517611A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528179A5 (cg-RX-API-DMAC7.html) | ||
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| JP2016513704A5 (cg-RX-API-DMAC7.html) | ||
| JP2013503134A5 (cg-RX-API-DMAC7.html) | ||
| JP2016537326A5 (cg-RX-API-DMAC7.html) | ||
| JP2014524476A5 (cg-RX-API-DMAC7.html) | ||
| KR102612379B1 (ko) | 벤조푸란 유도체 자유 염기의 결정 및 제조 방법 | |
| JP2020521732A5 (cg-RX-API-DMAC7.html) | ||
| JP2019516749A5 (cg-RX-API-DMAC7.html) | ||
| RU2015134420A (ru) | Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты | |
| JP2021501766A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510768A5 (cg-RX-API-DMAC7.html) | ||
| FI3317264T3 (fi) | (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola | |
| JP2015516425A5 (cg-RX-API-DMAC7.html) | ||
| RU2013120549A (ru) | Новые кристаллические формы натриевой соли(4-{4-[5-(6-трифторметил-пиридин-3-иламино) пиридин-2-ил] фенил} циклогексил) уксусной кислоты | |
| JP2011515421A5 (cg-RX-API-DMAC7.html) | ||
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида | |
| RU2015113277A (ru) | Кристаллическтие соединения | |
| CA3140231A1 (en) | 3-aryloxyl-3-five-membered heteroaryl-propylamine compound, and crystal form and use thereof |